No influence of prednisolone on IGFBP-3 proteolysis in healthy young men.

What Was Tested

The paper reports a study of Human Growth Hormone and Prednisolone, published as a randomized controlled trial.

Who Took Part

According to the abstract, 8 adults were involved.

PubMed indexes the participants as adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The adults were allocated by chance, so the Human Growth Hormone group and the comparison group should start out alike.

Blinding on both sides kept the adults and researchers unaware of who received Human Growth Hormone.

Some adults received a placebo instead of Human Growth Hormone, giving a reference point.

Each person switched between Human Growth Hormone and the comparison at some point, usually with a gap in between.

The researchers measured IGF-I, IGF-II, IGFBP-1, IGFBP-2, IGFBP-3 by immunoassays, IGFBP-3 by Western ligand blotting (WLB) and finally in vitro IGFBP-3 proteolysis by a (125)I-IGFBP-3 degradation assay.

What Was Measured

PubMed files the paper under topics including Blotting, Western, Drug Interactions, Human Growth Hormone, Immunoassay, Insulin-Like Growth Factor Binding Protein 1, Insulin-Like Growth Factor Binding Protein 2 and Insulin-Like Growth Factor Binding Protein 3.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Human Growth Hormone and Prednisolone in 8 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2001 (Hormone research), a journal based in Switzerland.

More context: the related Exogenous HGH, sermorelin & older GHRPs (why they're passed over) library page, all human trials.